Grifols, S.A. — FY2023 Form 20-F
Reporting period: Fiscal year ended December 31, 2023; the filing is an annual report, not a standalone Q4 report. It does not provide clear standalone Q4 financial results. Financial statements are prepared under IFRS as issued by the IASB and presented in euros.
Business context and results
Grifols is a global plasma-derived medicines and diagnostics company. Biopharma generated 84.3% of 2023 revenue; the United States and Canada represented 59.1% of revenue. The company reported more than 390 plasma collection centers and annual fractionation capacity exceeding 20 million liters.
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Net revenue | €6.592bn | €6.064bn | +8.7%; +10.9% at constant currency |
| Gross profit / margin | €2.495bn / 37.8% | €2.232bn / 36.8% | Margin +1.0 percentage point |
| Operating result | €799.4m | €805.7m | -0.8% |
| Profit before tax | €224.0m | €361.3m | -38.0% |
| Consolidated net profit | €180.7m | €271.1m | -33.4% |
| Profit attributable to Grifols shareholders | €59.3m | €208.3m | Down materially |
| Operating cash flow | €208.3m | -€10.9m | Improved |
Revenue growth was led by Biopharma, up 11.1% reported (13.3% constant currency). Immunoglobulin revenue rose 14.9% reported, while albumin sales increased 17.6%. Diagnostic revenue was broadly flat (-0.2% reported; +2.3% constant currency); Bio Supplies grew 9.5%. Lower plasma costs and operational savings supported margin improvement. Cost of sales fell to 62.2% of revenue from 63.2%.
Cash flow, debt and liquidity
- Cash and cash equivalents were €529.6m at year-end. Reported liquidity was €1.145bn, including €615.3m of unused credit facilities.
- Current and non-current financial liabilities totaled €11.057bn (€10.034bn non-current and €1.024bn current). The filing identifies €39.0bn? No: variable-rate senior debt was $2.3bn and €2.0bn, or 39% of senior interest-bearing debt. Do not confuse this with total financial liabilities.
- Finance result was a loss of €574.5m, versus €442.9m in 2022, largely reflecting higher interest rates on variable-rate debt. A 100-basis-point rate increase was estimated to raise annual interest expense by €34.1m.
- Investing cash outflow was €397.6m and financing cash inflow €186.0m. Reported capital expenditures were €281.5m; broader additions of property, equipment, intangibles and rights of use totaled €548.9m.
- Working capital absorbed €369.6m, chiefly as inventories increased €427.1m. Inventory days rose to 308 from 296.
Material changes, outlook and risks
- Operational Improvement Plan: Management reported 10% higher plasma collections and a 15.2% lower average plasma cost per liter in 2023. The plan reduced plasma collections per employee? The filing reports a 32% increase in collections per full-time employee and a 5% reduction in manufacturing costs versus 2022. It recorded €159.3m of reorganization charges, mainly severance and advisory costs, and targets more than €450m of annualized savings versus the 2022 cost base. Because of an approximately nine-month inventory accounting lag, some savings were expected to appear in 2024 results. This is a plan, not guaranteed guidance.
- Shanghai RAAS: A December 2023 agreement to sell a 20% stake to Haier for approximately $1.8bn was pending regulatory approvals at the filing date. Grifols said proceeds would be used to reduce debt. The agreement includes a GDS EBITDA commitment of $850m over 2024–2028 and potential indemnification if the target is missed, as well as minimum albumin supply commitments.
- Debt management: The company said it was pursuing new senior secured notes to refinance the 2017 Notes due 2025. It committed to medium-term deleveraging, lower dividends and no material acquisitions in the medium term. It did not propose a 2023 dividend and said cash dividends were not expected until leverage fell below 4.00:1.00.
- Governance and reporting controls: Management and KPMG identified material weaknesses in IT general controls and review/approval controls for certain recurring manual journal entries. KPMG issued an adverse opinion on internal control over financial reporting, but an unqualified opinion on the financial statements. The weaknesses did not result in identified misstatements; remediation was underway and not yet complete.
- ImmunoTek accounting: The CNMV concluded in March 2024 that the ImmunoTek arrangement should have been accounted for as a joint arrangement under IFRS 11 rather than a financial investment. The filing says the accounting was changed prospectively from January 1, 2023, with a €39.3m adjustment to reserves. The CNMV also cited disclosure improvements, while stating it found no need for a financial statement restatement and no evidence that reported indebtedness was inconsistent with the facts.
- Other significant matters: Short-seller reports in early 2024 drove substantial share-price volatility and prompted CNMV and SEC inquiries. The CNMV reported no need for restatement; SEC information requests were ongoing as of the filing. The company also disclosed a $16.75m settlement of an Illinois biometric privacy class action and an unresolved Abbott royalty/patent dispute. Plasma supply, manufacturing quality and regulation, competition and reimbursement, foreign exchange, interest rates, and high leverage remain key risks.
Most important facts for investors to verify
- Debt balances, maturities, covenant headroom, refinancing progress, and the company’s precise net-debt and leverage calculations.
- Whether the Shanghai RAAS sale closes, proceeds are received and applied to debt, and the GDS EBITDA and supply commitments are met.
- Whether the €450m-plus savings target is achieved and how much flows through to 2024 operating results and cash generation.
- Progress in remediating IT and manual journal-entry control weaknesses, including evidence that controls operate effectively.
- Consistent presentation and reconciliation of non-IFRS indicators, particularly EBITDA and debt/EBITDA, and further disclosure regarding the ImmunoTek accounting change.
- Plasma collection volumes, cost per liter, inventory levels and cash conversion, alongside competitive and pricing trends in immunoglobulins.